ITM Radiopharma: ENETS 2023

Our Mission

We aim to provide the most precise cancer radiodiagnostics and therapeutics to fight hard-to-treat tumors. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. We are leveraging our radioisotope leadership to advance a broad pipeline of Targeted Radionuclide Therapies for helping patients live longer and better.

Watch the introduction below and register now to access all of our recordings from ENETS 2023

All of the speakers' videos and presentations are available online upon registration.

A short story of NET therapy – from cold to hot somatostatin
Prof. Kjell Öberg, Professor of Endocrine Oncology, Uppsala University, Finland

Already have an account? Log in

We look back on a truly enlightening and sucessful ENETS 2023 conference. We will inform you once the ITM satellite content is available.

Meet the change-makers

Kjell Öberg

Professor, Endocrine Oncology

Senior Professor, Dept of Medical Sciences

Senior Advisor, Dept of Endocrine Oncology - University Hospital

Uppsala University

Aldo Scarpa

Director, ARC-Net Research Centre for Applied Research on Cancer

Director, Dept of Pathology

University and Hospital Trust of Verona

Wolfgang A. Weber

Chair, Dept of Nuclear Medicine

Full Professor, Nuclear Medicine

Technical University of Munich

Heloisa Soares

Associate Professor, Huntsman Cancer Institute

University of Utah

Kjell Öberg, Professor of Endocrine Oncology, Uppsala University, former chairman of the Dept. of Endocrine Oncology, University Hospital. One of the founders of ENETS and NANETS with 650 publications.

Pioneering treatment with somatostatin analogs and IFN, PET imaging, biomarkers: CgA, NETest.

Aldo Scarpa is Chair of the Department of Pathology at the University of Verona and Director of the ARC-Net Centre for Applied Research on Cancer. He received his MD from the University of Padua and his PhD in Molecular Pathology from the University of Verona. He trained in several international centres in Europe, USA and Japan. The research focus of Prof Scarpa is the translation into clinical practice of molecular subclassifications of cancers with prognostic-diagnostic-therapeutic relevance. He has published over 700 papers with an H index of 92. His interest in neuroendocrine neoplasms dates back to 1992 and ranges from histopathology and staging/grading to molecular characterisation as testified by his scientific production in the field.

Wolfgang Weber, MD is Professor and Chair of the Department of Nuclear Medicine at the Technical University of Munich in Germany (TUM). Dr. Weber’s research is focused on molecular imaging of cancer for planning and monitoring of therapeutic interventions. He is also interested in targeted radionuclide therapy of cancer and theranostics.

Dr. Heloisa Soares is a medical oncologist with a focus in neuroendocrine cancer. She is an associate professor at the Huntsman Cancer Institute (HCI) at University of Utah. She serves as the Medical Director for the Clinical Trials Office as well as the co-physician leader in the GI Clinical Trials Research Group at HCI. In 2019, she was elected as a member of the board of directors for The North American Neuroendocrine Tumor Society (NANETS). Additionally, she is a member of the NCI NET taskforce and part of the Neuroendocrine and Adrenal Tumors NCCN Clinical Practice Guidelines in Oncology. Currently, she is the National PI for the first adjuvant clinical trial in pancreas nets.